SEARCH

SEARCH BY CITATION

References

  • 1
    Schwab RS. Symptomatology and medical treatment of Parkinson’s disease. Int J Neurol 1961; 2: 6161.
  • 2
    Strang RR. The association of gastro-duodenal ulceration with Parkinson’s disease. Med J Austr 1965; 52: 842 3.
  • 3
    Szabo S. Dopamine disorder in duodenal ulceration. Lancet 1979; ii: 880 2.
  • 4
    Glavin GB. Activity of selective dopamine DA1 and DA2 agonists and antagonists on experimental gastric lesions and gastric acid secretion. J Pharmacol Exp Ther 1989; 251: 726 30.
  • 5
    Xing L, Washington J, Seaton J, Kauffman G. Monoamine oxidase B inhibition reduces gastric mucosal blood flow, basal acid secretion, and cold water restraint-induced gastric mucosal injury in rats. Dig Dis Sci 1990; 35: 61 5.
  • 6
    Sikiric P, Rotkvic I, Mise S, et al. Dopamine agonists prevent duodenal ulcer relapse. Dig Dis Sci 1991; 36: 905 10.
  • 7
    Szabo S. Experimental basis for a role for sulfhydryls and dopamine in ulcerogenesis: a primer for cytoprotection-organoprotection. Klin Wochenschr 1986; 64: 116 22.
  • 8
    Glavin GB. Dopamine and gastroprotection. The brain-gut axis. Dig Dis Sci 1991; 36: 1670 2.
  • 9
    Glavin GB & Hall AM. Brain-gut relationships: gastric mucosal defense is also important. Acta Physiol Hungarica 1992; 80: 107 15.
  • 10
    Altschuler E. Gastric Helicobacter pylori infection as a cause of idiopathic Parkinson’s disease and non-arteric anterior optic ischemic neuropathy . Med Hypotheses 1996; 47: 413 4.
  • 11
    Warren JR & Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; i: 1273 5.
  • 12
    Charlett A, Dobbs SM, Dobbs RJ, Weller C. Link between Helicobacter pylori infection and idiopathic parkinsonism. Med Hypotheses 2000; 55: 93 98.
  • 13
    Charlett A, Dobbs RJ, Dobbs SM, Weller C, Brady P, Peterson DW. Parkinsonism: siblings share Helicobacter pylori seropositivity and facets of syndrome. Acta Neurol Scand 1999; 99: 26 35.
  • 14
    Charlett A, Dobbs RJ, Purkiss AG, et al. Cortisol is higher in parkinsonism and associated with gait deficit. Acta Neurol Scand 1998; 97: 77 85.
  • 15
    Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW. Association of circulating TNF-α and IL-6 with ageing and parkinsonism. Acta Neurol Scand 1999; 100: 34 41.
  • 16
    Webster DD. Clinical analysis of the disability of Parkinson’s disease. Modern Treatments 1968; 5: 257 82.
  • 17
    Hoehn MM & Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427 42.
  • 18
    Quinn NP & Hussain FA. Parkinson’s disease. Br Med J 1986; 293: 379 81.
  • 19
    Quinn NP. Parkinsonism—recognition and differential diagnosis. Br Med J 1995; 310: 447 52.
  • 20
    Pahwa R & Koller CK. Defining Parkinson’s disease and Parkinsonism. In: Ellenberg JH, Koller WC, Langston JW, eds. Etiology of Parkinson’s Disease Neurological Disease and Therapy 40. New York: Marcel Dekker Inc., 1995: 1–54.
  • 21
    Medical Research Council. Memorandum No 45. Aids to the examination of the peripheral nervous system. London: Her Majesty’s Stationery Office, 1975.
  • 22
    Denham MJ & Jefferys P. Modified Tooting Bec Questionnaire. In: Source Book of Geriatric Assessement. Hampshire: Karger, 1984; 2: 52.
  • 23
    Statacorp. Stata Statistical Software: Release 5.0. College Station, Texas: Stata Corporation, 1997.
  • 24
    Murray LJ, McCrum EE, Evans AE, Bamford KB. Epidemiology of Helicobacter pylori infection among 4742 randomly selected subjects from Northern Ireland. Int J Epidemiol 1997; 26: 880 7.
  • 25
    Baumann RJ, Jameson D, McKean HE, et al. Cigarette smoking and Parkinson’s disease: 1. A comparison of cases with matched neighbours. Neurology 1980; 30: 839 43.
  • 26
    Kurland LT. Epidemiology: incidence, geographic distribution and genetic considerations. In: Field WS. ed. Pathogenesis and Treatment of Parkinsonism. Springfield IL: Charles C Thomas, 1958: 5–49.
  • 27
    Ben-Shlomom Y. The epidemiology of Parkinson’s disease. Bailliére’s Clin Neurol 1997; 6: 55 67.
  • 28
    Martyn CN & Osmond C. Parkinson’s disease and the environment in early life. J Neurol Sci 1995; 132: 201 6.
  • 29
    Dobbs RJ, Bowes SG, Charlett A, et al. Hypothesis: The bradyphrenia of Parkinsonism is a nosological entity. Acta Neurol Scand 1993; 87: 255 61.
  • 30
    Dobbs RJ, Bowes SG, Henley M, et al. Assessment of the bradyphrenia of Parkinsonism: a novel use of delayed auditory feedback. Acta Neurol Scand 1993; 87: 262 7.
  • 31
    Mathialogan R, Loizoa S, Beales ILP, et al. Who gets false-negative H. pylori (HP) ELISA results? Gut 1994; 35(Suppl. 5): S51S51.
  • 32
    Edwards LI, Quigley EMM, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease: frequency and pathophysiology. Neurology 1992; 42: 726 32.
  • 33
    Singaram C, Ashraf W, Guamnitz EA, et al. Dopaminergic defect of enteric nervous system in Parkinson’s disease patients with chronic constipation. Lancet 1995; 346: 861 4.
  • 34
    Kuposky WJ, Grimes MM, Sweeting J, Bertsch R, Cote LJ. Parkinson’s disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology 1987; 37: 1253 5.
  • 35
    Duvoisin RC. Is Parkinson’s disease acquired or inherited? Can J Neurol Sci 1984; 11: 151 5.
  • 36
    Barbeau A & Roy M. Familial subsets in idiopathic Parkinson’s disease. Can J Neurol Sci 1984; 11: 144 50.
  • 37
    Charlett A, Dobbs RJ, Dobbs SM, Peterson DW, Weller C. Is Helicobacter pylori antigen responsible for changes in circulating immunoglobulin associated with ageing? Br J Pharmacol 1999; 127(Suppl.): 80P80P.
  • 38
    Negrini R, Lisato L, Zanella I, et al. Helicobacter pylori infection induces antibodies cross-reacting with human gastric mucosa. Gastroenterology 1991; 101: 437 45.
  • 39
    Appelmelk BJ, Negrini R, Moran AP, Kuipers EJ. Molecular mimicry between Helicobacter pylori and the host. Trends Microbiol 1997; 5: 70 3.
  • 40
    Banatvala N, Mayo K, Megraud F, et al. The cohort effect and Helicobacter pylori. J Infect Dis 1993; 168: 219 21.
  • 41
    Calne DB, Eisen A, McGeer E, Spencer P. Alzheimer’s disease, Parkinson’s disease, and motoneurone disease: abiotrophic interaction between ageing and environment? Lancet 1986; ii: 1067 70.
  • 42
    Poupard A & Emile J. Autoimmunity in Parkinson’s disease. In: Hassler RG, Christ JF, eds. Parkinson-specific motor and mental disorders. Role of the pallidum: pathophysiological, biochemical and therapeutic aspects. Adv Neurol 40. New York: Raven Press, 1984: 315–23.
  • 43
    McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 1988; 38: 1285 9.
  • 44
    Dahlström A, Wigander D, Lundmark K, Gottfries C-G, Carvey PM, McRae A. Investigations on auto-antibodies in Alzheimer’s and Parkinson’s diseases, using defined neuronal cultures. J Neural Transm 1990; 29(Suppl.): 195 206.
  • 45
    Fiszer U, Mix E, Fredrikson S, Kostulas V, Olsson T, Link H. γδ+ T cells are increased in patients with Parkinson’s disease. J Neurol Sci 1994; 121: 39 45.
  • 46
    Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC. Immunocytochemical analysis of tumour necrosis factor and its receptors in Parkinson’s disease. Neurosci Lett 1994; 172: 151 4.
  • 47
    Mogi M, Harada M, Kondo T, et al. Interleukin-1-beta, interleukin-6, epidermal growth-factor-alpha and transforming growth-factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 1994; 180: 147 50.
  • 48
    Fiszer U, Mix E, Fredrikson S, Kostulas V, Link H. Parkinson’s disease and immunological abnormalities: increase of HLA-DR expression on monocytes in cerebrospinal fluid and of CD45RO+ T cells in peripheral blood. Acta Neurol Scand 1994; 90: 160 6.
  • 49
    Chiba S, Matsumoto H, Saitoh M, Kasahara M, Matsuya M, Kashiwagi M. A correlation study between serum adenosine-deaminase activities and peripheral lymphocyte subsets in Parkinson’s disease. J Neurol Sci 1995; 132: 170 3.
  • 50
    Mogi M, Harada M, Narabayashi H, Ingaki H, Minami M, Nagatsu T. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson’s disease. Neurosc Lett 1996; 211: 13 6.
  • 51
    Fiszer U, Fredrikson S, Czlonkowska A. Humoral response to hsp 65 and hsp 70 in cerebrospinal fluid in Parkinson’s disease. J Neurol Sci 1996; 139: 66 70.
  • 52
    Purkiss AG, Charlett A, Weller C, Dobbs SM, Dobbs RJ. Association of serum immunoglobulin subclasses IgA1 and IgA2 with facets of parkinsonism in sufferers and controls. Br J Clin Pharmacol 1998; 45: 207207.
  • 53
    Chen S, Le WD, Xie WJ, et al. Experimental destruction of substantia nigra initiated by Parkinson disease immunoglobulins. Arch Neurol 1998; 55: 1075 80.
  • 54
    Drumm B, Perez Perez GI, Blaser MJ, Sherman PM. Intrafamilial clustering of Helicobacter pylori infection. N Engl J Med 1990; 322: 358 63.
  • 55
    Parente F, Maconi G, Sangaletti O, et al. Prevalence of Helicobacter pylori infection and related gastroduodenal lesions in spouses of Helicobacter pylori positive patients with duodenal ulcer. Gut 1996; 35: 629 33.
  • 56
    Weller C, Nicholson PW, Dobbs SM, Bowes SG, Purkiss A, Dobbs RJ. Reduced axial rotation in the spouses of sufferers from idiopathic parkinsonism. Age Ageing 1992; 21: 189 94.
  • 57
    Kirollos C, O’Neill CJA, Dobbs RJ, et al. Quantification of the cardinal signs of parkinsonism and of associated disability in spouses of sufferers. Age Ageing 1993; 22: 20 6.
  • 58
    Kirollos C, Charlett A, O’Neill CJA, et al. Objective measurement of activation of rigidity: diagnostic, pathogenetic and therapeutic implications in parkinsonism. Br J Clin Pharmacol 1996; 41: 557 64.
  • 59
    O’Neill CJA, Richardson MD, Charlett A, et al. Could seborrhoeic dermatitis be implicated in the pathogenesis of parkinsonism? Acta Neurol Scand 1994; 89: 252 7.